AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - AtriCure reported revenue of $123.62 million for Q1 2025, a 13.6% increase year-over-year, with an EPS of -$0.14 compared to -$0.25 a year ago, exceeding the Zacks Consensus Estimate of $123.43 million by 0.16% and delivering an EPS surprise of 44% [1] Revenue Performance - U.S. Revenue in Pain Management reached $17.27 million, surpassing the average estimate of $16.17 million by analysts, reflecting a year-over-year increase of 35.6% [4] - Total U.S. Revenue was $101.15 million, exceeding the average estimate of $100.60 million, with a year-over-year change of 12.1% [4] - International Revenue in Pain Management was $1.79 million, slightly below the estimated $1.92 million, but showed a significant year-over-year increase of 90.9% [4] - Total International Revenue was $22.47 million, slightly below the average estimate of $22.70 million, with a year-over-year change of 20.8% [4] Segment Performance - International Revenue from Minimally Invasive Ablation was $2.01 million, below the estimated $2.37 million, representing a year-over-year decrease of 4.8% [4] - International Revenue from Appendage Management was $9.67 million, slightly above the average estimate of $9.60 million, with a year-over-year increase of 26.5% [4] - U.S. Revenue from Open Ablation was $33.31 million, close to the average estimate of $33.41 million, reflecting a year-over-year increase of 13.7% [4] - U.S. Revenue from Minimally Invasive Ablation was $8.48 million, significantly below the estimated $10.82 million, showing a year-over-year decrease of 31.2% [4] - U.S. Revenue from Appendage Management was $42.09 million, exceeding the average estimate of $40.21 million, with a year-over-year increase of 17.3% [4] Stock Performance - AtriCure's shares have returned 4.4% over the past month, outperforming the Zacks S&P 500 composite, which declined by 0.8% [3]